Introduction {#s5}
============

Misuse of alcohol is a major global public health issue. Alcohol misuse remains extremely common in the United States, where it is estimated that roughly 6.4% of the population age 12 years or older meets criteria for alcohol use disorder ([@CIT0013]), and alcohol misuse results in roughly 88 000 deaths per year (including alcohol-related motor vehicle accidents) ([@CIT0022]).

Alcohol use disorders are frequently comorbid with depressive symptoms in psychiatric clinical populations, and the combination results in an increased severity of both conditions, including an increased risk for suicidality (reviewed in [@CIT0014]). Human and animal data have provided ample justification to test antidepressants in clinical trials for alcohol use disorders with (and without) comorbid depressive symptoms; however, results from these studies have been disappointing, especially with regard to continued alcohol use ([@CIT0014]; [@CIT0008]).

Citalopram, a highly selective selective serotonin reuptake inhibitor (SSRI), has been used clinically since 1989, is available in generic formulations, and is FDA-approved for the treatment of major depressive disorder ([@CIT0002]). The i.v. administration of serotonergic agents has been studied as a means to speed the time needed to remit depressive symptoms in patients with major depressive disorder (reviewed in [@CIT0012]).

In alcohol-dependent (AD) participants, visual and olfactory cues reliably increase craving in a manner that is sensitive to pharmacological and environmental manipulation ([@CIT0018]). Cue-induced craving accompanies increased blood flow, specifically in the nucleus accumbens/ventral striatum in AD individuals, as an indirect measure of increased dopamine signaling, and this cue-induced craving is associated with lower baseline levels of dopamine D~2/3~ receptor availability ([@CIT0006], 2005). Additionally, AD individuals, on average, have been shown to have lower striatal dopamine receptor D~2/3~ receptor availability than control participants, as measured with positron emission tomography (PET) and the dopamine D~2/3~ receptor radioligand \[^18^F\]-desmethoxyfallypride ([@CIT0006])

Chronic oral citalopram (20 mg/d for 14 days) results in decreased striatal dopamine receptor binding potential compared with placebo (using PET scanning and the dopamine D~2/3~ receptor ligand \[^11^C\]-raclopride), an indication of increased intrasynaptic dopamine concentration, but a single dose of oral citalopram has not been shown to affect striatal dopamine binding potential ([@CIT0025]). A single i.v. infusion of citalopram (40 mg) decreased dopamine D~2/3~ receptor binding potential in the human striatum to a degree comparable with that seen in the earlier study of chronic oral citalopram dosing ([@CIT0025]; [@CIT0020]). Therefore, we chose to study single-dose i.v. citalopram administration to test for SSRI-induced changes in cue-induced craving for alcohol and concomitant dopamine signaling in subcortical regions in AD research participants compared with matched healthy nondrinking control participants.

METHODS {#s6}
=======

Overview of Study Procedures {#s7}
----------------------------

All procedures were approved by the Veterans Administration Greater Los Angeles institutional review board. Participants were enrolled and screened on the first visit. Qualifying participants were invited back for 3 subsequent visits: a structural MRI scan and 2 study medication/\[^18^F\]-fallypride PET scanning days (citalopram 40 mg i.v., or saline placebo, double-blinded, administered in counter-balancing order) more than 1 week apart. All completing participants had breathalyzer-confirmed exhaled alcohol concentration of 0 and alcohol withdrawal scores (confirming no intoxication and minimal alcohol withdrawal symptoms) on all study visits (Clinical Institute Withdrawal Assessment for Alcohol \[CIWA\] \< 10). On study medication/PET scanning days, the following procedures were completed in order: (1) breathalyzer, withdrawal, and psychiatric symptomatology screening; (2) i.v. citalopram (or saline placebo) infusion (1 hour); (3) cue-induced craving assessment (approximately 20 minutes); and (4) \[^18^F\]-fallypride PET scanning (approximately 3 hours). Smoking was allowed during study days but proscribed for 2 hours prior to PET scanning.

Research Participants {#s8}
---------------------

AD and healthy control (HC) participants were screened via the SCID-IV, excluding any participants with any Axis I psychiatric diagnosis within the last 6 months (aside from nicotine dependence in both groups and alcohol dependence in the AD group). Fourteen potential AD and 17 potential HC participants were enrolled and screened. Ten participants in each group completed the study. Alcohol dependence in potential participants was confirmed using the SCID-IV diagnostic criteria. AD participants were active drinkers with no history of complicated alcohol withdrawal symptoms who agreed to stop drinking by 6:00 pm on the day prior to all study procedure days; significant alcohol withdrawal symptoms on study procedure days (CIWA \> 10) was exclusionary. Inclusion criteria included age 21 to 55 years and no recent use (last 30 days) of any psychoactive medications. All participants had a normal physical exam, EKG, and laboratory studies, along with negative alcohol breathalyzer and saliva toxicology screens for opiates, benzodiazepines, amphetamine, cocaine, and cannabinoids on study days. Of the participants who completed the study, 7 AD and 6 HC participants had analyzable PET scan data due to technical PET scanning issues (PET scanner malfunction or radiosynthesis failure).

Assessments {#s9}
-----------

Baseline rating scales included the Beck Depression Inventory-II to test for current depression/suicidality ([@CIT0001]) and the CIWA ([@CIT0023]; score \<10 needed on all study days to ensure safe participation). Recent (last 90 days) average alcohol intake was assessed using the Timeline Follow Back assessment ([@CIT0021]). Craving for alcohol was assessed using the Alcohol Urge Questionnaire (AUQ) ([@CIT0010]).

Intravenous Citalopram Infusions {#s10}
--------------------------------

Intravenous citalopram (Seropram) was provided by Lundbeck (Copenhagen, Denmark). On infusion days, participants received 40 mg i.v. citalopram or saline placebo in a double-blinded manner, followed by the assessments described below. Citalopram and counter-balanced saline placebo was infused in 250 mL of normal saline over 1 hour by infusion pump on separate scanning days. Two to 3 hours after the infusion was completed, participants underwent PET scanning. PET scans were acquired after administration of 5 mCi of \[^18^F\]-fallypride, in two 80-minute blocks separated by a 20-minute break. The mean (SD) dose of \[^18^F\]-fallypride received by participants was 4.96 (0.20) mCi. Participants returned at least 1 week later to complete the second infusion/PET scan, counter-balanced. They completed the study after the second infusion/PET scan day.

Cue-Induced Craving Assessment {#s11}
------------------------------

Cue reactivity was assessed after each of the intravenous infusions (i.e., citalopram 40 mg or saline control) and followed standardized procedures as described ([@CIT0011]; [@CIT0018]). After each period, craving was assessed using the AUQ. The mean of the 3 AUQ determinations was used as a covariate in further data analysis to compare with PET results. Craving scores were assessed by repeated-measures ANOVA.

MRI and PET Scans and Analyses {#s12}
------------------------------

Details of research structural MRI scans (acquired on a 3-T Siemens tomograph) and \[^18^F\]-fallypride (approximately 5 mCi) PET scans have been described previously ([@CIT0016]). \[^18^F\]-fallypride was synthesized in the cyclotron facility of the VA by procedures described previously ([@CIT0009]), supported by an Investigational New Drug application (no. 78 226) from the FDA. Each batch of radiotracer was tested for quality control, including radiochemical purity, specific activity, and apyrogenicity. All complete scans were analyzed for all subjects, with the result being that no partially completed studies (e.g., having only one PET scan for a given subject) were available.

PET Volume of Interest (VOI) and Whole-Brain Voxelwise Analysis {#s13}
---------------------------------------------------------------

Reconstructed PET data were automatically segmented into standardized subcortical VOIs, and VOI binding potential (BP~ND~) was estimated using the simplified reference tissue modeling with the cerebellum as the reference region via PMOD Kinetic Modeling (PMOD Technologies Ltd., Zurich, Switzerland) (see [@CIT0017] for more detail). VOIs were established for the following brain regions: striatum (caudate nucleus, putamen, and nucleus accumbens as separate VOIs), amygdala, hippocampus, globus pallidus, and thalamus.

Correlation analyses for region-specific dopamine D~2/3~ receptor BP~ND~ and mean cue-induced craving were done using Spearman rank coefficient testing. A further test of the association between cue-induced craving and regional BP~ND~ (group × BP~ND~ interaction) was conducted with a whole-brain voxelwise analyses. Voxelwise parcellation of BP~ND~ estimation was done using FSL. ANOVA for effect of craving and group was done using SPM12 ([@CIT0003]). All whole-brain voxelwise BP~ND~ statistics were computed with a voxel height threshold of F = 86.5 (*P* \< .0001), minimum cluster size of n = 20 voxels, and family-wise error correction of *P* \< .0001 for correction for multiple comparisons.

RESULTS {#s14}
=======

Demographics {#s15}
------------

The AD and HC groups did not differ in mean age (38 \[7.6\] vs 41 \[7.9\] years, *P* = .38), sex distribution (8/10 vs 5/10 males, *P* = 0.44), fraction of ethnically white individuals (5/10 vs 4/10, *P* = .52), years education (12.9 \[1.5\] vs 13.8 \[1.4\], *P* = .2), or intake Beck Depression Inventory (9.5 \[8.1\] vs. 3.9 \[4.2\], *P* = .08). Therefore, subsequent analyses were not adjusted for demographic or clinical variables that did not differ between study groups. Seven AD participants but none of the HC participants were current smokers (though 7 of the HC group were former smokers; *P* = .003). Current smoking and AD status were highly collinear, as smoking is highly prevalent in individuals with alcohol dependence; therefore, smoking status was excluded from subsequent analysis ([@CIT0004]). AD participants reported consuming 6.9 (2.3) drinks per day on average in the 90 days prior to study entry, whereas HC participants reported consuming 0.1 (0.14) drink per day (*P* \< .0001).

Cue-Induced Alcohol Craving: Effect of i.v. Citalopram {#s16}
------------------------------------------------------

Cue-induced alcohol craving was decreased by a single infusion of i.v. citalopram compared with saline placebo in AD participants (*P* = .003). Notably, there was a low baseline level of cue-induced craving for alcohol in HC participants, and it tended to decrease with i.v. citalopram as well, compared with saline placebo (*P* = .06). There was no group × citalopram interaction (F~(1,17)~ = 1.28; *P* = .27).

Thalamic Dopamine D~2/3~ BP~ND~ Levels in AD Participants {#s17}
---------------------------------------------------------

Using ANOVA, there was a strong trend to decreased thalamic (but not striatal) dopamine D~2/3~ BP~ND~ in AD participants compared with HC participants (2.7 vs 2.1; uncorrected *P* = .014; see [Table 1](#T1){ref-type="table"}). However, after Bonferroni correction for multiple comparisons, the group difference in thalamic 18F-fallypride BP~ND~ did not meet *P* = .05 significance criteria ([Table 1](#T1){ref-type="table"}). No overall effect of condition (i.v. citalopram vs saline placebo) on regional BP~ND~ was found ([Table 1](#T1){ref-type="table"}), although a trend to reduced BP~ND~ is seen in the thalamus (*P* = .06 uncorrected).

###### 

D~2/3~ Receptor Binding Potential ANOVA Results

  Region              Group         Condition   
  ------------------- ------- ----- ----------- -----
  Amygdala            0.01    .92   0.09        .77
  Caudate             1.07    .32   0.98        .34
  Hippocampus         0.96    .35   0.92        .36
  Nucleus accumbens   0.03    .87   2.02        .18
  Pallidus            3.55    .09   1.56        .24
  Putamen             1.70    .22   0.87        .37
  Thalamus            8.62    .01   4.47        .06

F and *P* values indicate ANOVA results for region BPND for group and condition effects. Condition = saline vs citalopram. Listed *P* values are uncorrected. After Bonferonni correction for multiple comparisons, none of the *P* values fall below the *P* \< .05 significance threshold.

Correlations between Cue-Induced Alcohol Craving and D~2/3~ BP~ND~ {#s18}
------------------------------------------------------------------

There was a strong correlation between mean cue-induced craving for alcohol and thalamic D~2/3~ BP~ND~ across all participants and conditions, even after correction for multiple comparisons (*P* = .0003 uncorrected; [Figure 1A](#F1){ref-type="fig"}). There were no correlations between mean cue-induced craving for alcohol and region-specific BP~ND~ values in other regions tested.

![Thalamic dopamine binding potential (BP~ND~) correlates with mean cue-induced craving scores in alcohol-dependent (AD) and healthy control (HC) subjects. Correlation between thalamic dopamine BPND and mean scores of cue-induced craving (Alcohol Urge Questionnaire \[AUQ\]). (A) Region-specific volume of interest (VOI) correlations. Group = participant group; cond = condition (active- citalopram, saline- placebo). Red indicates AD participants, blue indicates HC participants, circles indicate citalopram, triangles indicate saline. Diagonal line indicates linear correlation (coefficient r = −0.59) across conditions and participant groups. (B) Heat map of voxelwise correlation between dopamine D~2/3~ receptor BP~ND~ and mean cue-induced craving. Coronal section at z = 7 mm representing a map of mean voxelwise correlation between dopamine D~2/3~ receptor BP~ND~ and mean cue-induced craving. Average voxelwise binding was warped into a sample participant MRI for demonstration purposes. Colors correspond to the F value of relevant voxelwise correlations, with strongest correlations seen in the bilateral thalamus (F values \> 3000) after family-wise error correction of *P* \< .0001 for multiple comparisons.](pyz010f0001){#F1}

Whole-brain voxelwise BP~ND~ analysis with mean cue-induced craving for alcohol as a covariate demonstrates strong correlations in bilateral thalamic regions (*P* \< .0001), with weaker correlations in other subcortical regions, across conditions ([Figure 1B](#F1){ref-type="fig"}). There were also weaker signals for bilateral amygdalae, and left stronger than right Brodmann's Area 38 cortical regions.

Discussion {#s19}
==========

Single-Dose i.v. Citalopram Reduces Cue-Induced Alcohol Craving {#s20}
---------------------------------------------------------------

The results demonstrate that a single infusion of i.v. citalopram (40 mg) reduces cue-induced alcohol craving. Although many studies have shown the potential for a differential response to SSRIs in subtypes of AD individuals ("type I vs II" and "type A vs B"; [@CIT0008]), all of our participants had less craving for alcohol in the citalopram than the placebo condition. Given that there was no association between changes in dopaminergic neurotransmission and changes in cue-induced craving for alcohol, it is likely that the mechanism of action of single-dose i.v. citalopram craving attenuation is independent of changes in striatal dopamine.

No Effect of Single-Dose i.v. Citalopram on Striatal BP~ND~ as Assessed by Fallypride PET Scanning {#s21}
--------------------------------------------------------------------------------------------------

Although a prior study with \[^11^C\]-raclopride showed that a single dose of i.v. citalopram decreased striatal dopamine receptor availability significantly, albeit only by approximately 5% ([@CIT0020]), the current results showed not even a trend for a change in striatal BP~ND~ with i.v. citalopram, as measured with \[^18^F\]-fallypride PET scanning ([Table 1](#T1){ref-type="table"}). However, given the relatively lower affinity of \[^11^C\]-raclopride for dopamine D~2/3~ receptors compared with \[^18^F\]-fallypride, these results may be explained by pharmacology and neurophysiology (see following section for a more complete explanation).

Reduced Dopamine Receptor Availability in Alcohol Dependence: Thalamus in Fallypride Studies, Striatum in Raclopride Studies {#s22}
----------------------------------------------------------------------------------------------------------------------------

Previous studies have shown mixed results when assessing whether AD individuals have lower striatal dopamine receptor availability than controls using various weakly binding PET ligands (such as \[^11^C\]-raclopride; cf [@CIT0015]). However, one prior study showed that AD individuals at admission to a hospital program had lower thalamic (but not striatal) dopamine D~2/3~ receptor availability than controls using the PET ligand \[^18^F\]-fallypride ([@CIT0019]). Similarly, our study demonstrates a strong trend that actively drinking AD participants have lower thalamic dopamine D~2/3~ receptor availability than comparison HC participants with \[^18^F\]-fallypride, consistent with findings in ([@CIT0019]). Although fallypride has a greater affinity for dopamine D~2~ receptors than D~3~ receptors, a prior finding that the thalamus contains a higher level of D~3~ receptors than D~2~ receptors indicates that some of the thalamic differences we have observed may actually represent reduced thalamic D~3~ receptors in alcoholics compared with matched controls ([@CIT0024]). Future studies may consider investigating both thalamic dopamine D~2~ and D~3~ receptor availability separately in alcohol use disorder.

Alcohol Use Disorder: Aberrant Striatal Dopamine Signaling? {#s23}
-----------------------------------------------------------

Our results and prior studies described above are consistent with the notion that alcohol use disorder represents a striatal hyperdopaminergic state ([@CIT0007]). Autoradiographic studies of human postmortem brain tissue (corroborated by a rodent model for alcohol use disorder) demonstrate that individuals with alcohol use disorder do not differ from controls in striatal dopamine D~2~ receptor density or D~2~ mRNA levels but do have lower dopamine transporter density ([@CIT0007]). However, it should be noted that the findings of [@CIT0007] may conflict with some earlier animal and human postmortem findings. The possibility that striatal alterations in alcohol dependence are more likely due to increased dopamine release rather than reduced dopamine receptor availability is broadly consistent with the results of this study, but more studies are needed to confirm this hypothesis.

Correlation of Cue-Induced Craving for Alcohol With Thalamic Dopamine D~2/3~ Receptor BP~ND~ {#s24}
--------------------------------------------------------------------------------------------

Our finding of a strong correlation between cue-induced craving for alcohol and thalamic dopamine D~2/3~ receptor availability in a group of AD and HC individuals is novel. Thalamic dopamine signaling has been little-studied in the field of alcohol use disorders. However, the results presented here, combined with the earlier demonstration that AD individuals had lower thalamic dopamine D~2/3~ receptor availability than controls, should stimulate future studies on the role of aberrant thalamic dopamine signaling in alcohol use disorders ([@CIT0019]). Interestingly, these results parallel those of a prior study showing that methylphenidate-induced craving for cocaine in cocaine-dependent subjects was also correlated with reduced thalamic dopamine receptor availability, indicating that aberrant thalamic dopamine signaling may represent a more widespread feature of substance use disorders ([@CIT0026]).

Limitations {#s25}
-----------

A limitation of the study is the modest sample size, which was (at least partly) due to the detailed study methods (including 2 full day sessions, including PET scanning, per participant). Another limitation was that, due to the extensive collinearity between smoking and alcohol dependence in the sample, we were unable to effectively disentangle any specific effect of smoking status on any of the measures reported. Additionally, we did not keep track of smoking behavior on study days of our smoking participants (aside from proscribing smoking for 2 hours prior to PET scanning), which may have influenced dopamine binding potential measurements. We did not keep track of the last drink consumed by participants prior to study procedures, though all participants were breathalyzer-negative during all procedures. Our samples represent approximately equal numbers of males and females and therefore may obscure any gender-specific effect on any of the reported measures. We excluded participants with active psychiatric illness and those taking psychoactive medications; thus, these findings may not generalize to clinical samples of patients with alcohol use disorder where psychiatric comorbidities are common.

Conclusions {#s26}
===========

A single dose of i.v. citalopram reduces cue-induced craving for alcohol in AD participants. As noted above, it is unlikely that our observed decrease in cue-induced craving with a single dose of i.v. citalopram is due to any changes in brain dopamine release. Cue-induced craving for alcohol is highly correlated with thalamic dopamine D~2/3~ receptor availability in a mixed group of AD and HC research participants. The overall results are broadly consistent with the striatal hyperdopaminergic hypothesis of alcohol dependence, whereby increased dopamine release, rather than reduced postsynaptic dopamine receptor activity, is likely to be the major striatal dopaminergic neurochemical alteration.
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